PATH-11. PROSPECTIVE (EPI-)GENETIC CLASSIFICATION OF > 1, 000 PEDIATRIC CNS TUMORS—THE MNP 2.0 STUDY. (4th December 2020)

• Record Type: Journal Article
• Authors: Sturm, Dominik; Sahm, Felix; Andreiuolo, Felipe; Capper, David; Gessi, Marco; Rode, Agata; Bison, Brigitte; Hirsch, Steffen; Gerber, Nicolas U; Gottardo, Nicholas G; Kramm, Christof M; Rutkowski, Stefan; von Deimling, Andreas; Pietsch, Torsten; Pfister, Stefan M; Jones, David T W
• Is Part Of: Neuro-oncology. Volume 22(2020)Supplement 3
• Page Start: iii426
• Page End: iii426
• Publication Date: 2020-12-04
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noaa222.647
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: The large variety of CNS tumor entities affecting children and adolescents, some of which are exceedingly rare, results in very diverging patient outcomes and renders accurate diagnosis challenging. To assess the diagnostic utility of routine DNA methylation-based CNS tumor classification and gene panel sequencing, the Molecular Neuropathology 2.0 study prospectively integrated these (epi-)genetic analyses with reference neuropathological diagnostics as an international trial for newly-diagnosed pediatric patients. In a four-year period, 1, 215 patients with sufficient tissue were enrolled from 65 centers, receiving a reference neuropathological diagnosis according to the WHO classification in >97%. Using 10 FFPE sections as input, DNA methylation analysis was successfully performed in 95% of cases, of which 78% with sufficient tumor cell content were assigned to a distinct epigenetic tumor class. The remaining 22% did not match any of 82 represented classes, indicating novel rare tumor entities. Targeted gene panel sequencing of >130 genes performed for 96% of patients with matched blood samples detected diagnostically, prognostically, or therapeutically relevant somatic alterations in 48%. Germline DNA sequencing data indicated potential predisposition syndromes in ~10% of patients. Discrepant results by neuropathological and epigenetic classification (29%) were enriched in histological high-grade gliomas and implicated clinical relevance in 5% of all cases. Clinical follow-up suggests improved survival for some patients with high-grade glioma histology and lower-grade molecular profiles. Routine (epi-)genetic profiling at the time of primary diagnosis adds a valuable layer of information to neuropathological diagnostics and will improve clinical management of CNS tumors.